Modality
Degrader
MOA
CD3xCD20
Target
GPRC5D
Pathway
JAK/STAT
Pancreatic CaBladder Ca
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
~Nov 2019
→ ~Feb 2021
Phase 2
May 2021
→ Oct 2025
Phase 2Current
NCT04923547
1,900 pts·Pancreatic Ca
2021-05→2025-10·Recruiting
1,900 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-205mo agoPh2 Data· Pancreatic Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2025-10-20 · 5mo ago
Pancreatic Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04923547 | Phase 2 | Pancreatic Ca | Recruiting | 1900 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |